Answers are grounded in this paper and cite their sources.
Doxorubicin is a prototypical inducer of immunogenic cell death (ICD) that sensitizes to subsequent immunotherapy by PD-1 blockade. However, this systemic drug combination fails against glioblastoma, hidden behind the blood-brain barrier (BBB). A recent work delineates a biophysical method for BBB permeabilization that yields effective preclinical effects of chemoimmunotherapy.
No takes yet. Share an insight, caveat, or question.
Pol et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: